Showing 891-900 of 1635 results for "".
- EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restorethttps://modernod.com/news/eyebio-announces-positive-visual-anatomic-and-safety-data-from-first-in-human-ph1b2a-amarone-trial-of-restoret/2482112/Eyebiotech announced the presentation of Week 12 data from its first-in-human phase 1b/2a AMARONE trial of Restoret in patients with treatment-naïve diabetic macular edema (DME) and treatment-naïve wet age-related macular degeneration (AMD). The analysis was presented by Charles C.
- Oyster Point Pharma Announces Tyrvaya Nasal Spray Now Covered by Express Scriptshttps://modernod.com/news/oyster-point-pharma-announces-tyrvaya-nasal-spray-now-covered-by-express-scripts/2480656/Oyster Point Pharma announced Tyrvaya Nasal Spray’s placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively covers an estimated 26 million people, effective February 19, 2022. Tyrvaya is the first and only na
- Alimera Announces Multiple Abstracts Highlighting ILUVIEN Real-World Data at EURETINA Annual Congresshttps://modernod.com/news/alimera-announces-multiple-abstracts-highlighting-iluvien-real-world-data-at-euretina-annual-congress/2481055/Alimera Sciences announced that clinical data for ILUVIEN (fluocinolone acetonide intravitreal implant 0.19mg) will be featured in more than 20 scientific abstracts during the EURETINA 2022 congress being held in Hamburg, Germany from September 1-4, 2022. Audio Na
- Gottlieb’s Quick Goodbye Triggers Investor Panic, Biopharma Bewildermenthttps://modernod.com/news/gottliebs-quick-goodbye-triggers-investor-panic-biopharma-bewilderment/2476360/When FDA Commissioner Scott Gottlieb got his job, critics called him a shill and industry types figured they’d gained a friend in the most important drug regulatory agency in the world. It didn’t turn out quite that way. Gottlieb was biopharma-friendly—to the point where the Na
- Nanoscope Announces 3-Year Vision Improvements from REMAIN Study of MCO-010 in RPhttps://modernod.com/news/nanoscope-announces-3-year-vision-improvements-from-remain-study-of-mco-010-in-retinitis-pigmentosa/2484207/Nanoscope Therapeutics announced 3-year follow-up data from the REMAIN study, the long-term extension of its pivotal phase 2b/3 RESTORE trial evaluating MCO-010, the company’s proprietary optogenetic therapy for retinitis pigmentosa (RP).
- FDA Selects Dompé for National Priority Voucher Program to Accelerate Development of Novel Intranasal Therapyhttps://modernod.com/news/fda-selects-dompe-for-national-priority-voucher-program-to-accelerate-development-of-novel-intranasal-therapy/2484190/Dompé announced its selection by the FDA to participate in the Commissioner’s National Priority Voucher (CNPV) program. Through this designation, Dompé has been awarded a voucher granting a signific
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- Nanoscope to Present Long-Term Data for MCO-010 in RP at Euretina and Retina Society 2025https://modernod.com/news/nanoscope-to-present-long-term-data-for-mco-010-in-rp-at-euretina-and-retina-society-2025/2484129/Nanoscope Therapeutics announced it will present new long-term data from its RESTORE follow-up study, REMAIN, at two major international meetings: the 2025 Euretina Congress in Paris and the 2025 Retina Society Annual Scientific Meeting in Chicago.
- Vision Advocates Rally to Defend National Eye Institute from Funding Cuts and Consolidation Threatshttps://modernod.com/news/vision-advocates-rally-to-defend-national-eye-institute-from-funding-cuts-and-consolidation-threats/2482913/Vision science and eye care organizations are mobilizing efforts to combat proposals circulating in Washington to slash federal vision funding and consolidate the National Eye Institute (NEI) into a broader institute on brain and dental research.
- Nanoscope Initiates Rolling Submission of BLA to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat RPhttps://modernod.com/news/nanoscope-initiates-rolling-submission-of-bla-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-rp/2482884/Nanoscope Therapeutics announced the initiation of a rolling submission of a biologics license application (BLA) to the FDA for its lead investigational therapy, MCO-010, for the treatment of severe vision loss due to retinitis pigmentosa (RP). This marks a significant re